Last reviewed · How we verify
NCT03464396: PreVent
Prematurity-Related Ventilatory Control
trial testing Bedside Physiology study in Respiratory Control in Premature Infants in 177 participants. Completed in 9 March 2022.
9 February 2022
Quick facts
| Lead sponsor | Washington University School of Medicine |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 177 |
| Start date | 14 May 2018 |
| Primary completion | 9 February 2022 |
| Estimated completion | 9 March 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Bedside Physiology study
- Carotid Body Function Test
- Room Air Challenge
- Hypoxia Challenge Test
- Effects of Nasal Cannula Flow
- Magnetic Resonance Imaging
- Echocardiogram
- Blood Sample — full drug profile →
Conditions studied
- Respiratory Control in Premature Infants — all drugs for Respiratory Control in Premature Infants →
Sponsor
Washington University School of Medicine
Who can join
Adults 1 Day to 28 Days, any sex, with Respiratory Control in Premature Infants. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research study is to improve our understanding of unstable breathing and heart blood flow patterns seen in premature infants. The investigator will use novel non-invasive measures to understand the determinants of these unstable breathing and heart flow patterns to potentially identify new therapies for their prevention.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Quantitative and Qualitative Changes in Peripheral Chemoreceptor Activity in Preterm Infants.
Mammel DM, Carroll JL, Warner BB, Edwards BA, et al · · 2023 · cited 3× · PMID 36173816 · DOI 10.1164/rccm.202206-1033oc
Verify or expand the search:
- PubMed search for NCT03464396
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Washington University School of Medicine trials
Trials by the same sponsor.
- NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
- NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
- NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
- NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03464396 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
- Last refreshed: 31 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03464396.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing